FindTrial
Sign In

AG881

DRUG4 trials

Sponsors

Institut de Recherches Internationales Servier, Agios Pharmaceuticals, Inc.

Conditions

Acute Myeloid Leukemia (AML)GliomaHealthy VolunteersHematologic MalignanciesMyelodysplastic Syndrome

Phase 1

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
CompletedNCT02481154
Institut de Recherches Internationales ServierGlioma
Start: 2015-06-01End: 2024-06-19Updated: 2026-02-17
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
CompletedNCT02492737
Agios Pharmaceuticals, Inc.Acute Myeloid Leukemia (AML), Hematologic Malignancies, Myelodysplastic Syndrome
Start: 2015-08-07End: 2018-03-21Updated: 2019-03-08
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
CompletedNCT03343197
Institut de Recherches Internationales ServierGlioma
Start: 2018-03-20End: 2025-03-28Updated: 2026-02-17
A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants
CompletedNCT04145128
Agios Pharmaceuticals, Inc.Healthy Volunteers
Start: 2019-10-02End: 2019-12-18Updated: 2020-04-02

Related Papers

10309- ACT-18 A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN DIFFUSE GLIOMA WITH AN IDH1 MUTATION: UPDATED RESULTS
Neuro-Oncology Advances2024-11-29
CTNI-47. A PHASE 1, RANDOMIZED, PERIOPERATIVE TRIAL OF VORASIDENIB AND IVOSIDENIB IN IDH1-MUTANT DIFFUSE GLIOMA: UPDATED RESULTS
Neuro-Oncology2024-11-012 citations
Safety, efficacy, and <scp>PK</scp>/<scp>PD</scp> of vorasidenib in previously treated patients with <scp>m</scp><i>IDH1/2</i> hematologic malignancies: A phase 1 study
American Journal of Hematology2023-06-248 citations
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Nature Medicine2023-02-23188 citations
NIMG-41. PH-WEIGHTED MOLECULAR MRI AS AN EARLY BIOMARKER OF METABOLIC RESPONSE TO IDH INHIBITION IN IDH MUTANT GLIOMAS
Neuro-Oncology2021-11-02
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Clinical Cancer Research2021-06-02233 citations
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
HemaSphere2021-06-0112 citations
Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected m<i>IDH1</i> lower-grade glioma (LGG).
Journal of Clinical Oncology2021-05-206 citations
Abstract 2046: Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment
Cancer Research2020-08-154 citations
Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.
Journal of Clinical Oncology2020-05-208 citations
PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1
Neuro-Oncology2019-08-0111 citations
Abstract 2275: Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinoma
Cancer Research2019-07-012 citations
Abstract 2275: Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinoma
Clinical Research (Excluding Clinical Trials)2019-07-01
A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.
Journal of Clinical Oncology2019-05-2033 citations
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Investigational New Drugs2019-04-2695 citations
RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA
Neuro-Oncology2018-11-014 citations
Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.
Journal of Clinical Oncology2018-05-2035 citations
Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies
Molecular Cancer Therapeutics2018-01-0118 citations